Deutsche Bank Aktiengesellschaft Issues Pessimistic Forecast for Hikma Pharmaceuticals (LON:HIK) Stock Price

Hikma Pharmaceuticals (LON:HIK) had its price target cut by investment analysts at Deutsche Bank Aktiengesellschaft from GBX 3,100 ($42.10) to GBX 2,850 ($38.70) in a report released on Tuesday, MarketBeat reports. The firm currently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s price target indicates a potential upside of 57.91% from the company’s current price.

A number of other research firms also recently commented on HIK. Jefferies Financial Group restated a “buy” rating and set a GBX 2,600 ($35.31) price objective on shares of Hikma Pharmaceuticals in a research note on Thursday, August 7th. JPMorgan Chase & Co. reduced their price objective on shares of Hikma Pharmaceuticals from GBX 2,600 ($35.31) to GBX 2,500 ($33.95) and set an “overweight” rating for the company in a research note on Friday, August 8th.

Hikma Pharmaceuticals Price Performance

Shares of LON HIK opened at GBX 1,804.79 ($24.51) on Tuesday. The firm has a market cap of £5.00 billion, a PE ratio of 17.71, a PEG ratio of 2.38 and a beta of 0.41. The company has a current ratio of 1.66, a quick ratio of 1.27 and a debt-to-equity ratio of 55.82. Hikma Pharmaceuticals has a 1-year low of GBX 1,690 ($22.95) and a 1-year high of GBX 2,360 ($32.05). The company has a fifty day moving average price of GBX 1,989.71 and a 200 day moving average price of GBX 2,042.98.

Insider Transactions at Hikma Pharmaceuticals

In related news, insider Said Darwazah sold 13,863 shares of the firm’s stock in a transaction dated Friday, May 30th. The shares were sold at an average price of GBX 2,138 ($29.03), for a total value of £296,390.94 ($402,486.34). Also, insider Mazen Darwazah bought 200,000 shares of the business’s stock in a transaction that occurred on Thursday, August 7th. The stock was purchased at an average price of GBX 1,756 ($23.85) per share, with a total value of £3,512,000 ($4,769,147.20). Corporate insiders own 30.54% of the company’s stock.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.